Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme
7 affiliations
- 1Department of Dermatology, Instituto Dermatologico de Jalisco, “Dr. Jose Barba Rubio”, University of Guadalajara, Guadalajara, Mexico
- 2Pfizer Inc, 66 Hudson Boulevard East, New York, NY 10001-2192 USA
- 3Adelphi Real World, Bollington, UK
- 4Dr. Valentin Gomez Farias Regional Hospital, Guadalajara, Mexico
- 5Pfizer Mexico, Mexico City, Mexico
- 6Dermatology Department, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico
- 7Clinical Science Department, School of Medicine, University of Monterrey, Dermatology Center of Monterrey, Monterrey, Mexico
Abstract
Introduction: Alopecia areata (AA) is a common autoimmune disease characterized by nonscarring hair loss, yet real-world data on AA in Mexico are sparse. This study aimed to characterize disease burden and identify unmet treatment needs among patients with AA in Mexico.
Methods: Clinical data were analyzed from Adelphi Real World’s AA II Mexico Disease Specific Programme™ (October 2024–April 2025), a linked physician and patient cross-sectional survey with retrospective elements. Dermatologists provided clinical and treatment information for eight consecutive patients with AA within prespecified severity quotas (three mild, three moderate, and two severe/very severe). Patients completed the Hospital Anxiety and Depression Scale, the Alopecia Areata Patient Priority Outcomes instrument, and the Skindex-16 AA questionnaire. Analyses were stratified by physician-assessed AA severity (mild, moderate, severe/very severe).
Results: Of the 319 patients included, 123 had mild, 112 moderate, and 84 severe/very severe AA. Disease duration, percent scalp hair loss, nonscalp hair loss (eyebrow, eyelash, and body), and hair regrowth at consultation differed significantly across severity groups. Traditional medications, such as intralesional, topical, and oral corticosteroids, were the most frequently prescribed treatments across all severity groups. Physician-reported satisfaction with current treatment decreased with increasing AA severity and was significantly different across severity groups (P < 0.0001). Overall, 23.0% of patients with moderate AA and 29.0% with severe/very severe AA reported satisfaction with their current treatment and believed the best control had been achieved compared with 60.6% of patients with mild AA (P < 0.0001). Patients with severe/very severe AA experienced greater quality-of-life impairment and higher rates of anxiety and depression.
Conclusion: This study helps address the gap in real-world evidence on AA in Mexico. The reliance on traditional therapies, combined with low treatment satisfaction among physicians and patients with moderate to very severe AA, suggests a need for improved access to advanced therapies within the Mexican healthcare system.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01943-3.
Related
- Early-onset colorectal cancer in Korea: clinical characteristics, treatment patterns, and survival outcomes in a K-CURE nationwide population-based study
- Real-World Clinicopathological Characteristics, Metastatic Distribution, and Treatment Patterns of Triple-Negative Breast Cancer: A Single-Institution Experience from Nigeria
- The Characteristics and Clinical Evolution of Adolescents With Severe Chronic Pain in an Inpatient Multimodal Pain Programme
- Associations of outdoor physical activity, screen time, and sleep characteristics with myopia among primary and secondary school students
- Participant Characteristics Associated With Loneliness Reduction During a Digital Social Robot Intervention Among Older Adults Living Alone in Japan: Secondary Analysis of a Randomized Controlled Trial
BibTeX
@article{sanchezduenas2026describing,
title = {{Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme}},
author = {Luis E. Sanchez-Duenas and Ashley S. Cha-Silva and Peter Anderson and Martha Alicia Aceves-Villalvazo and Veronica J. Guajardo-Barron and Carlos A. Barrera-Ochoa and Raul A. Becerra-Cerecedo and Jorge Alberto Barragan Garfias and William Jones and Samantha K. Kurosky and Nelly A. Espinoza-Gonzalez},
journal = {Dermatology and Therapy},
year = {2026},
month = oct,
doi = {10.1007/s13555-026-01943-3},
url = {https://doi.org/10.1007/s13555-026-01943-3},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme
AU - Luis E. Sanchez-Duenas
AU - Ashley S. Cha-Silva
AU - Peter Anderson
AU - Martha Alicia Aceves-Villalvazo
AU - Veronica J. Guajardo-Barron
AU - Carlos A. Barrera-Ochoa
AU - Raul A. Becerra-Cerecedo
AU - Jorge Alberto Barragan Garfias
AU - William Jones
AU - Samantha K. Kurosky
AU - Nelly A. Espinoza-Gonzalez
PY - 2026
DA - 2026/10/07
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01943-3
UR - https://doi.org/10.1007/s13555-026-01943-3
AB - Introduction: Alopecia areata (AA) is a common autoimmune disease characterized by nonscarring hair loss, yet real-world data on AA in Mexico are sparse. This study aimed to characterize disease burden and identify unmet treatment needs among patients with AA in Mexico. Methods: Clinical data were analyzed from Adelphi Real World’s AA II Mexico Disease Specific Programme™ (October 2024–April 2025), a linked physician and patient cross-sectional survey with retrospective elements. Dermatologists provided clinical and treatment information for eight consecutive patients with AA within prespecified severity quotas (three mild, three moderate, and two severe/very severe). Patients completed the Hospital Anxiety and Depression Scale, the Alopecia Areata Patient Priority Outcomes instrument, and the Skindex-16 AA questionnaire. Analyses were stratified by physician-assessed AA severity (mild, moderate, severe/very severe). Results: Of the 319 patients included, 123 had mild, 112 moderate, and 84 severe/very severe AA. Disease duration, percent scalp hair loss, nonscalp hair loss (eyebrow, eyelash, and body), and hair regrowth at consultation differed significantly across severity groups. Traditional medications, such as intralesional, topical, and oral corticosteroids, were the most frequently prescribed treatments across all severity groups. Physician-reported satisfaction with current treatment decreased with increasing AA severity and was significantly different across severity groups (P < 0.0001). Overall, 23.0% of patients with moderate AA and 29.0% with severe/very severe AA reported satisfaction with their current treatment and believed the best control had been achieved compared with 60.6% of patients with mild AA (P < 0.0001). Patients with severe/very severe AA experienced greater quality-of-life impairment and higher rates of anxiety and depression. Conclusion: This study helps address the gap in real-world evidence on AA in Mexico. The reliance on traditional therapies, combined with low treatment satisfaction among physicians and patients with moderate to very severe AA, suggests a need for improved access to advanced therapies within the Mexican healthcare system. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01943-3.
SN - 2193-8210
SN - 2190-9172
SN - 1476-5829
ER -